UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, highlighting the company's strategic focus on value-generating transactions and advancements in their product pipeline [1][3]. Company Developments - Cyprium Therapeutics has transferred the development and commercialization rights of ZYCUBO to Sentynl Therapeutics, which was approved by the FDA on January 12, 2026, for treating Menkes disease [2]. - The PRV was issued following the FDA approval of ZYCUBO, and Cyprium is set to receive tiered royalties on net sales and up to $129 million in development and sales milestones from Sentynl [2]. - Cyprium is obligated to pay 20% of the PRV sale proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development [2]. Strategic Positioning - Fortress Biotech's Chairman emphasized the significance of the PRV sale and recent FDA approvals for their products, indicating a strong position to execute on their portfolio [3]. - Cyprium's recent achievements include the approval of ZYCUBO and the execution of the asset sale, with plans to advance AAV-ATP7A Gene Therapy for Menkes disease [3]. Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development for clinical development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed products and multiple development programs across various therapeutic areas [5].